MetaCap

HUTCHMED (China) Limited ADR (HCM)

NASDAQ: HCMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.22-0.23 (-1.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HCM stock chart

Technical analysis

Key statistics

All statistics
P/E (TTM)
132.20
52-week range
9.77 – 16.33
Day range
13.13 – 13.45
Volume / Avg
32.80K / 64.48K
Beta
—

52-week range

$9.77$16.33

HCM stock today

On Nov 20, HCM ended the session at $13.22, shedding $0.23 (1.71%), versus the S&P 500's 3.70% decline. At this level, HCM sits in the middle of its 52-week range of $9.77 to $16.33: 19.0% below the high, set on Jan 16, 2026 and 35.3% above the low. HCM is down 0.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.6%.

HUTCHMED (China) trades at 132.2x its trailing twelve-month earnings per share of $0.10. Its forward P/E of 51.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About HUTCHMED (China)

Company profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Chig Fung Cheng BEc, CA
Headquarters
Hong Kong
Employees
1,790
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, HUTCHMED (China) generated $548.5 million in revenue, down 13.0% from fiscal 2024, its first annual decline since 2024. Net income was $456.9 million (+1111.0% year over year), for a net margin of 83.3% versus a median of -54.7% in the prior 5 years. Gross margin was 38.7% (down from 44.6%) and operating margin -7.1%.

HUTCHMED (China) annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$548.51M$630.20M$838.00M$426.41M$356.13M
Growth-12.96%-24.80%+96.52%+19.73%+56.21%
Net income$456.91M$37.73M$100.78M$-360.83M$-194.65M
EPS (diluted)$0.52$0.04$0.12$-0.43$-0.25

Analyst forecast

Forecast

Consensus (11 analysts)

none

Avg. price target

$21.14+59.91%

  • Strong buy 1
  • Buy 9
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $13.60High $33.27

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

HCM news

All HCM news

HUTCHMED (China) peers

Health Care sector
HCM peer companies
CompanyPrice% ChgMarket capCompare
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs HCM
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs HCM
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs HCM
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs HCM
NAMSNewAmsterdam Pharma Company N.V.18.41-5.64%$2.21Bvs HCM
LKFTLakefront Biotherapeutics ADR33.31-0.24%$2.18Bvs HCM
MBXMBX Biosciences Inc.49.55-7.23%$2.46Bvs HCM
IDYAIDEAYA Biosciences Inc.25.56-2.33%$2.47Bvs HCM

Indexes, lists and sector

HUTCHMED (China) stock FAQ

What is HUTCHMED (China)'s stock price today?

HCM last traded at $13.22 as of Nov 20, 4:00 PM EST, down 1.71% on the day. Prices are delayed at least 15 minutes.

What is HCM's P/E ratio?

HCM trades at a trailing P/E ratio of 132.20 and a forward P/E of 51.00.

Who is HUTCHMED (China)'s CEO?

Mr. Chig Fung Cheng BEc, CA is the chief executive officer of HUTCHMED (China) Limited ADR, which has about 1,790 employees.

What is the HCM 52-week high?

The 52-week high for HCM is $16.33 and the 52-week low is $9.77. The stock is currently 19.0% below its high.

Compare HCM